Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Current Investments (2016 - 2025)

Ani Pharmaceuticals' Cash & Current Investments history spans 16 years, with the latest figure at $285.6 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 97.12% year-over-year to $285.6 million; the TTM value through Dec 2025 reached $285.6 million, up 97.12%, while the annual FY2025 figure was $285.6 million, 97.12% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $285.6 million at Ani Pharmaceuticals, up from $262.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $285.6 million in Q4 2025 and bottomed at $15.3 million in Q3 2021.
  • The 5-year median for Cash & Current Investments is $145.0 million (2024), against an average of $137.6 million.
  • The largest annual shift saw Cash & Current Investments soared 718.38% in 2021 before it crashed 49.45% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $105.3 million in 2021, then plummeted by 49.45% to $53.2 million in 2022, then soared by 315.38% to $221.1 million in 2023, then crashed by 34.47% to $144.9 million in 2024, then soared by 97.12% to $285.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Cash & Current Investments are $285.6 million (Q4 2025), $262.6 million (Q3 2025), and $217.8 million (Q2 2025).